Share |

Content about Renal cell carcinoma

August 11, 2011

Novel Targeted Agents In Soft Tissue Sarcoma.

We are again speaking with Dr. John Eckardt on novel targeted agents in soft tissue sarcoma.

Welcome to the Oncology Network for Excellence. We are again speaking with Dr. John Eckardt on novel targeted agents in soft tissue sarcoma. Dr. Eckardt, in recent years, several previously unmet needs have been fulfilled as new targeted agents have emerged. Still today, one area of unmet need is sarcoma. Can you tell us what progress has been made in this area recently?

May 27, 2011

Overview of the Impact of Targeted Therapies on Selective Pathways

Today will be speaking with Dr. John Eckardt who will be discussing the 2011 American Society of Clinical Oncology Meeting.

Welcome to the Oncology Network for Excellence. Below is a transcript of our recent conversation with Dr. John Eckardt who provides us an overview on the impact of targeted therapies on selective pathways.

Dr. Eckardt is a board certified medical oncologist who has 20 years of experience in patient care, oncology drug development, and oncology education. Dr. Eckardt is now the Chief Medical Officer at DAVA Oncology.